129 related articles for article (PubMed ID: 7742473)
1. In vitro cytokine production by HLA-B8,DR3 positive subjects.
Candore G; Cigna D; Gervasi F; Colucci AT; Modica MA; Caruso C
Autoimmunity; 1994; 18(2):121-32. PubMed ID: 7742473
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects.
Modica MA; di Lorenzo G; Galluzzo A; Giordano C; Portelli MR; Candore G; Caruso C
Autoimmunity; 1990; 7(2-3):87-96. PubMed ID: 2104185
[TBL] [Abstract][Full Text] [Related]
3. HLA-B8,DR3 T cell impairment is completely restored by in vitro treatment with interleukin-2.
Candore G; Colucci AT; Modica MA; Caruso C
Immunopharmacol Immunotoxicol; 1991; 13(4):551-61. PubMed ID: 1774436
[TBL] [Abstract][Full Text] [Related]
4. In vitro impairment of interleukin-5 production in HLA-B8, DR3-positive individuals implications for immunoglobulin A synthesis dysfunction.
Lio D; D'Anna C; Gervasi F; Cigna D; Modica MA; Candore G; Caruso C
Hum Immunol; 1995 Nov; 44(3):170-4. PubMed ID: 8666553
[TBL] [Abstract][Full Text] [Related]
5. Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. II. Influence of the HLA B8, DR3, DQ2 haplotype.
Godot V; Harraga S; Beurton I; Tiberghien P; Sarciron E; Gottstein B; Vuitton DA
Clin Exp Immunol; 2000 Sep; 121(3):491-8. PubMed ID: 10971516
[TBL] [Abstract][Full Text] [Related]
6. Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity.
Lio D; Candore G; Romano GC; D'Anna C; Gervasi F; Di Lorenzo G; Modica MA; Potestio M; Caruso C
Cytokines Cell Mol Ther; 1997 Dec; 3(4):217-24. PubMed ID: 9740350
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3: role of interleukin-1.
Hashimoto S; Michalski JP; Berman MA; McCombs C
Clin Exp Immunol; 1990 Feb; 79(2):227-32. PubMed ID: 2311300
[TBL] [Abstract][Full Text] [Related]
8. Increased interleukin-2 receptor affinity in normal HLA A1 B8 DR3 subjects.
Pomier G; Vindimian M; Healy JC; Le Petit JC
J Immunogenet; 1990 Dec; 17(6):371-7. PubMed ID: 2096181
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3 in clinically healthy individuals.
Hashimoto S; McCombs CC; Michalski JP
Clin Exp Immunol; 1989 Jun; 76(3):317-23. PubMed ID: 2787712
[TBL] [Abstract][Full Text] [Related]
10. Individual susceptibility to hexavalent chromium of workers of shoe, hide, and leather industries. Immunological pattern of HLA-B8, DR3-positive subjects.
Mignini F; Streccioni V; Baldo M; Vitali M; Indraccolo U; Bernacchia G; Cocchioni M
Prev Med; 2004 Oct; 39(4):767-75. PubMed ID: 15351544
[TBL] [Abstract][Full Text] [Related]
11. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.
Stassi G; Todaro M; De Maria R; Candore G; Cigna D; Caruso C; Galluzzo A; Giordano C
Hum Immunol; 1997 Jun; 55(1):39-45. PubMed ID: 9328788
[TBL] [Abstract][Full Text] [Related]
12. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro.
Candore G; Cigna D; Todaro M; De Maria R; Stassi G; Giordano C; Caruso C
Hum Immunol; 1995 Apr; 42(4):289-94. PubMed ID: 7558912
[TBL] [Abstract][Full Text] [Related]
13. Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.
Caruso C; Candore G; Colucci AT; Cigna D; Modica MA; Tantillo G; Salerno A
Hum Immunol; 1993 Nov; 38(3):226-30. PubMed ID: 8106282
[TBL] [Abstract][Full Text] [Related]
14. HLA-B8,DR3 haplotype affects lymphocyte blood levels.
Caruso C; Bongiardina C; Candore G; Cigna D; Romano GC; Colucci AT; Di Lorenzo G; Gervasi F; Manno M; Potestio M; Tantillo G
Immunol Invest; 1997 Apr; 26(3):333-40. PubMed ID: 9129986
[TBL] [Abstract][Full Text] [Related]
15. HLA-B8,DR3 phenotype and lymphocyte responses to phytohaemagglutinin.
Modica MA; Cammarata G; Caruso C
J Immunogenet; 1990; 17(1-2):101-7. PubMed ID: 2212697
[TBL] [Abstract][Full Text] [Related]
16. Markers of T lymphocyte activation in HLA-B8, DR3 positive individuals.
Modica MA; Zambito AM; Candore G; Caruso C
Immunobiology; 1990 Nov; 181(4-5):257-66. PubMed ID: 2129202
[TBL] [Abstract][Full Text] [Related]
17. gamma-Interferon, interleukin-4 and interleukin-6 in vitro production in old subjects.
Candore G; Di Lorenzo G; Melluso M; Cigna D; Colucci AT; Modica MA; Caruso C
Autoimmunity; 1993; 16(4):275-80. PubMed ID: 8025206
[TBL] [Abstract][Full Text] [Related]
18. HLA-B8/DR3 phenotype and the primary immune response.
Kallenberg CG; Klaassen RJ; Beelen JM; The TH
Clin Immunol Immunopathol; 1985 Jan; 34(1):135-40. PubMed ID: 3871182
[TBL] [Abstract][Full Text] [Related]
19. Immunoglobulin genes, HLA-B8/DR3, and immune responsiveness to primary immunogen and mitogens in normal subjects.
Kallenberg CG; Klaassen RJ; Westra J; Beelen JM; Ockhuizen T
Clin Immunol Immunopathol; 1988 Jun; 47(3):333-42. PubMed ID: 3259481
[TBL] [Abstract][Full Text] [Related]
20. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity.
Lio D; Candore G; Colombo A; Colonna Romano G; Gervasi F; Marino V; Scola L; Caruso C
Hum Immunol; 2001 Jul; 62(7):705-13. PubMed ID: 11423177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
